Interventional Cardiology Devices Market By Product Type (Coronary Stents, PTCA (Balloon Catheters), Guidewires, Catheters (Diagnostic & Guiding), Plaque Modification Devices (Atherectomy), Others (Closure Devices, Accessories)), By Stent Type (Drug-Eluting Stents (DES), Bare-Metal Stents (BMS), Bioresorbable Stents), By Procedure Type (Coronary Angioplasty, Peripheral Interventions, Structural Heart Interventions, Other Interventions), By End User (Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers, Specialty Cardiac Clinics), By Application (Coronary Artery Disease (CAD), Myocardial Infarction, Peripheral Artery Disease, Congenital Heart Disease), By Access Route (Femoral Access, Radial Access), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Market Overview

Global Interventional Cardiology Devices Market size is expected to be worth around US$ 38.4 Billion by 2035 from US$ 17.6 Billion in 2025, growing at a CAGR of 8.1% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 41.0% share with a revenue of US$ 7.2 Billion.

The Interventional Cardiology Devices market plays a vital role in the treatment of coronary artery disease (CAD), structural heart disorders, and other cardiovascular conditions through minimally invasive catheter-based procedures. These devices include coronary stents, balloon catheters, guidewires, intravascular imaging systems, atherectomy devices, and hemodynamic support systems that enable physicians to restore blood flow while reducing the need for open-heart surgery.

Continuous technological improvements in drug-eluting stents, imaging-guided interventions, and transcatheter treatment techniques are improving procedural precision, patient safety, and long-term clinical outcomes. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) continue to evaluate and authorize innovative cardiovascular devices, supporting broader adoption of advanced interventional therapies.

As of March 2026, the FDA had granted 1,284 Breakthrough Device designations, with 198 marketing authorizations issued for breakthrough medical devices, reflecting sustained innovation across cardiovascular technologies.

Demand for interventional cardiology devices is closely linked to the growing global burden of cardiovascular disease. According to the U.S. Centers for Disease Control and Prevention (CDC), cardiovascular disease caused 919,032 deaths in the United States during 2023, representing approximately one in every three deaths, while someone experiences a heart attack every 40 seconds, with nearly 805,000 heart attacks occurring annually.

Coronary artery disease remains the most common form of heart disease, affecting about 5% of U.S. adults aged 20 years and older. These statistics highlight the continuing need for effective diagnostic and therapeutic interventions, supporting investments in advanced interventional cardiology technologies, hospital catheterization laboratories, and image-guided cardiovascular procedures worldwide.

Key Takeaways

• Market Size: Global Interventional Cardiology Devices Market size is expected to be worth around US$ 38.4 Billion by 2035 from US$ 17.6 Billion in 2025.
• Market Share: The market is growing at a CAGR of 8.1% during the forecast period from 2026 to 2035.
• Product Type: Coronary Stents dominated the Interventional Cardiology Devices Market with a 46.0% market share in 2025.
• Stent Type: Drug-Eluting Stents (DES) dominated the Interventional Cardiology Devices Market with a 78.0% market share in 2025.
• Procedure Type: Coronary Angioplasty dominated the Interventional Cardiology Devices Market with a 62.0% market share in 2025.
• End User: Hospitals dominated the Interventional Cardiology Devices Market with a 67.0% market share in 2025.
• Application: Coronary Artery Disease (CAD) dominated the Interventional Cardiology Devices Market with a 71.0% market share in 2025.
• Access Route: Femoral Access dominated the Interventional Cardiology Devices Market with a 54.0% market share in 2025.
• Regional Analysis: In 2025, North America led the market, achieving over 41.0% share with a revenue of US$ 7.2 Billion.

Product Type Analysis

Coronary Stents dominated the Interventional Cardiology Devices Market.

Coronary Stents dominated the Interventional Cardiology Devices Market with a 46.0% market share in 2025, making them the largest product category due to their central role in treating coronary artery disease and restoring blood flow in narrowed or blocked arteries.

The widespread adoption of drug-eluting and advanced stent technologies has improved procedural outcomes, reduced restenosis rates, and supported continued demand across hospitals and catheterization laboratories. Increasing volumes of percutaneous coronary interventions and the growing prevalence of cardiovascular disorders have further strengthened the position of coronary stents as the primary revenue-generating segment.

PTCA (Balloon Catheters) accounted for 24.0% of the market, supported by their essential use in vessel dilation during angioplasty procedures. Guidewires represented 12.0%, benefiting from their critical role in navigating complex vascular anatomy and enabling device delivery. Catheters (Diagnostic & Guiding) held 10.0% of the market as they remain indispensable for imaging, lesion assessment, and interventional access.

Plaque Modification Devices (Atherectomy) contributed 5.0%, driven by the rising treatment of heavily calcified and complex lesions where plaque removal enhances procedural success. The Others category, including Closure Devices and Accessories, represented 3.0% of the market, supported by increasing emphasis on procedural efficiency, vascular closure, and post-intervention patient management.

Stent Type Analysis

Drug-Eluting Stents (DES) dominated the Interventional Cardiology Devices Market.

Drug-Eluting Stents (DES) dominated the Interventional Cardiology Devices Market with a 78.0% market share in 2025, reflecting their widespread adoption as the preferred stent technology for coronary interventions.

DES release antiproliferative drugs that reduce the risk of restenosis and repeat revascularization, making them highly effective for long-term vessel patency. Continuous improvements in stent design, thinner struts, biocompatible polymers, and enhanced drug-delivery mechanisms have further strengthened their clinical acceptance.

The growing number of percutaneous coronary interventions and the increasing prevalence of coronary artery disease have also contributed to the strong demand for DES across hospitals and catheterization laboratories worldwide.

Bare-Metal Stents (BMS) accounted for 12.0% of the market, primarily used in specific patient populations where shorter durations of dual antiplatelet therapy are preferred. Although their use has declined compared with DES, BMS continue to maintain a presence in selected clinical scenarios and cost-sensitive healthcare settings.

Bioresorbable Stents represented 10.0% of the market, supported by growing interest in temporary scaffold technologies that gradually dissolve after vessel healing. Advances in bioresorbable materials, scaffold strength, and implantation techniques are expected to support future adoption, particularly for younger patients and cases requiring restoration of natural vessel function over the long term.

Procedure Type Analysis

Coronary Angioplasty dominated the Interventional Cardiology Devices Market.

Coronary Angioplasty dominated the Interventional Cardiology Devices Market with a 62.0% market share in 2025, driven by the high global burden of coronary artery disease and the widespread adoption of minimally invasive coronary interventions.

The procedure remains the primary treatment approach for opening narrowed or blocked coronary arteries using balloons and stents, offering faster recovery times and lower complication rates compared with traditional surgical methods.

Increasing numbers of percutaneous coronary interventions, improved catheter-based technologies, and expanding access to cardiac care have further strengthened the dominance of coronary angioplasty across hospitals and cardiac catheterization centers.

Peripheral Interventions accounted for 18.0% of the market, supported by the rising prevalence of peripheral artery disease and growing use of endovascular procedures to restore blood flow in peripheral vessels. Structural Heart Interventions represented 12.0%, benefiting from increasing adoption of transcatheter therapies for conditions such as aortic stenosis and other structural cardiac abnormalities.

Other Interventions held 8.0% of the market, including specialized catheter-based cardiovascular procedures that address a range of complex cardiac and vascular conditions. Advances in imaging guidance, device precision, and minimally invasive treatment techniques continue to expand the scope of interventional cardiology procedures, supporting growth across all procedure segments while maintaining coronary angioplasty as the leading category in 2025.

End User Analysis

Hospitals dominated the Interventional Cardiology Devices Market.

Hospitals dominated the Interventional Cardiology Devices Market with a 67.0% market share in 2025, driven by their comprehensive cardiovascular care capabilities, advanced catheterization facilities, and high patient volumes.

Hospitals remain the primary setting for complex interventional cardiology procedures, including coronary angioplasty, stent implantation, and structural heart interventions. Their access to specialized cardiologists, intensive care units, advanced imaging systems, and emergency cardiac services supports the large-scale adoption of interventional devices.

The growing burden of cardiovascular diseases and increasing numbers of minimally invasive cardiac procedures have further strengthened hospital demand for coronary stents, catheters, guidewires, and related devices.

Cardiac Catheterization Labs represented a significant share of the market as dedicated centers for diagnostic and therapeutic cardiovascular interventions. These facilities benefit from increasing procedure volumes, technological advancements, and expanding investment in specialized cardiac infrastructure.

Ambulatory Surgical Centers are gaining traction due to their cost-efficient care models, shorter patient stays, and growing ability to perform selected minimally invasive cardiovascular procedures. Specialty Cardiac Clinics also contribute to market growth by providing focused cardiac diagnosis, follow-up care, and outpatient interventional services.

Collectively, these end users are expanding access to cardiovascular treatment, while hospitals continue to dominate the market due to their broader procedural capabilities and integrated cardiac care services in 2025.

Application Analysis

Coronary Artery Disease (CAD) dominated the Interventional Cardiology Devices Market.

Coronary Artery Disease (CAD) dominated the Interventional Cardiology Devices Market with a 71.0% market share in 2025, reflecting the high global prevalence of atherosclerotic coronary disease and the extensive use of interventional procedures for its treatment.

The widespread adoption of coronary angioplasty, stent implantation, and catheter-based therapies has made CAD the largest application segment. Rising rates of hypertension, diabetes, obesity, smoking, and aging populations continue to increase the number of patients requiring minimally invasive coronary interventions.

Advances in drug-eluting stents, imaging-guided procedures, and plaque modification technologies have further improved treatment outcomes and supported strong demand for interventional cardiology devices in CAD management.

Myocardial Infarction represented an important application segment, driven by the need for rapid coronary revascularization during acute cardiac events. Early intervention with angioplasty and stenting has become a standard approach to restore blood flow and reduce heart muscle damage.

Peripheral Artery Disease contributed to market growth through increasing use of endovascular interventions to treat blocked peripheral vessels. Congenital Heart Disease also generated demand for specialized catheter-based devices used in correcting structural heart abnormalities.

While these applications continue to expand, CAD remains the dominant driver of the interventional cardiology devices market due to its large patient population and high procedural volume in 2025.

Access Route Analysis

Femoral Access dominated the Interventional Cardiology Devices Market.

Femoral Access dominated the Interventional Cardiology Devices Market with a 54.0% market share in 2025, remaining the most widely used access route for a broad range of coronary and peripheral interventions.

The femoral approach provides a larger arterial entry point, allowing physicians to use a wide variety of catheters, stents, atherectomy systems, and structural heart devices, particularly during complex procedures.

Its long-established clinical familiarity, suitability for large-bore device delivery, and effectiveness in challenging anatomical cases continue to support its leading position across hospitals and specialized cardiac centers. Femoral access is especially preferred for certain structural heart interventions, complex coronary procedures, and peripheral vascular treatments that require enhanced device support and maneuverability.

Radial Access represented the remaining share of the market and continues to gain significant momentum due to its lower bleeding risk, reduced vascular complications, improved patient comfort, and shorter recovery times. Increasing physician experience, advancements in catheter and guidewire technology, and growing adoption of same-day discharge protocols have accelerated the shift toward radial procedures in many healthcare facilities.

Despite the rapid expansion of radial access, femoral access maintained market leadership in 2025 because of its versatility, compatibility with complex interventions, and continued use in procedures requiring larger device profiles and advanced cardiovascular support systems.

Key Market Segments

Product Type

• Coronary Stents
• PTCA (Balloon Catheters)
• Guidewires
• Catheters (Diagnostic & Guiding)
• Plaque Modification Devices (Atherectomy)
• Others (Closure Devices, Accessories)

Stent Type

• Drug-Eluting Stents (DES)
• Bare-Metal Stents (BMS)
• Bioresorbable Stents

Procedure Type

• Coronary Angioplasty
• Peripheral Interventions
• Structural Heart Interventions
• Other Interventions

End User

• Hospitals
• Cardiac Catheterization Labs
• Ambulatory Surgical Centers
• Specialty Cardiac Clinics

Application

• Coronary Artery Disease (CAD)
• Myocardial Infarction
• Peripheral Artery Disease
• Congenital Heart Disease

Access Route

• Femoral Access
• Radial Access

Drivers

Aging CAD burden and riskfactor intensity.
Cardiovascular disease remains the largest structural demand engine for interventional cardiology because the addressable patient pool continues to widen faster than many hospital systems can fully absorb.

WHO still estimates about 17.9 million deaths annually from cardiovascular diseases globally, while CDC reports 919,032 U.S. cardiovascular deaths in 2023 and identifies coronary heart disease as the most common heartdisease subtype; CDC also notes more than $168 billion in U.S. heartdisease healthcare and medication costs between 2021 and 2022.

This matters commercially because higher prevalence of hypertension, cholesterol disorders, diabetes, and aginglinked calcific coronary disease raises the number of patients who progress from medical management to angiography, PCI, repeat revascularization, and adjunct imaging use.

In businessmodel terms, the driver lifts not just unit procedure volumes but also the mix of complex lesions, which increases catheterlab utilization, demand for premium wires, balloons, drugeluting stents, atherectomy or lithotripsy tools, and postPCI monitoring pathways.

The impact is strongest in North America, Europe, Japan, and urbanizing Asian corridors where older cohorts and metabolicrisk clustering support sustained referral growth rather than a onetime rebound.

Challenges

Data interoperability gaps limiting evidencedriven adoption.
A less visible but increasingly material challenge is fragmented data architecture across device registries, hospital IT stacks, UDI systems, postmarket surveillance files, and realworld evidence workflows, which raises the cost of proving clinical value and slows both regulatory and commercial execution.

Europe’s move toward mandatory EUDAMED usage for key modules from May 2026 improves traceability but also exposes how uneven manufacturer and provider data readiness still is, especially for firms trying to synchronize certificate data, device registration, surveillance records, field actions, and countrylevel compliance requirements across multiple jurisdictions.

This creates about 0.7% points of growth drag through duplicate data entry, slower recall response loops, delayed evidence generation, and weaker installedbase visibility, and it demands longhorizon investment in interoperable quality systems, UDIconnected commercial analytics, and registryconnected outcomes infrastructure that will likely take more than four years to harmonize meaningfully across the global interventional cardiology landscape.

Restraints

EU MDR transition extensions and cardiology device squeeze.

The supply of cardiovascular devices across the European Union continues to face significant constraints due to the implementation of the Medical Device Regulation (MDR) certification framework. Although the regulatory system has matured, it continues to prioritize compliance and patient safety over rapid market approvals.

The European Commission’s decision to extend transition deadlines for legacy medical devices into 2027–2028 indicates that certification capacity remains under pressure and has not yet fully normalized. As a result, manufacturers continue to experience delays in obtaining or renewing product approvals.

For interventional cardiology device manufacturers, these regulatory requirements create a substantial bottleneck. Even for products with established clinical performance, activities such as technical documentation updates, clinical evidence generation, sterilization and packaging validation, and notified-body assessments typically require approximately 13–18 months to complete under current MDR processes.

These lengthy review cycles particularly affect line extensions, product renewals, and specialized low-volume catheter families, where the commercial return may not justify repeated regulatory investment despite their clinical importance.

The European Society of Cardiology’s 2025 warning regarding the risk of “disappearing devices” further highlights the market impact of these challenges. The withdrawal of niche balloons, guidewires, access devices, and structural accessories reduces procedural flexibility for physicians, increases substitution costs, and encourages hospitals to stock only approved alternatives.

These factors collectively slow product innovation and adoption, contributing to lower market expansion and reducing the projected CAGR by approximately 1.4% points across the European cardiovascular device market.

Opportunity

Structural Heart Expansion Beyond Mature TAVR Platforms.

Future growth opportunities in the European cardiovascular device market are increasingly shifting beyond the mature transcatheter aortic valve replacement (TAVR) segment toward adjacent structural heart interventions.

High-potential areas include transcatheter tricuspid repair and replacement, pulmonary valve replacement, and therapies targeting right-heart diseases, all of which remain significantly underpenetrated despite growing clinical demand. While TAVR continues to serve as an established growth segment, these emerging therapies offer substantial long-term expansion potential.

Market demand is being supported by an aging population and the rising prevalence of ischemic heart disease and heart failure. However, commercialization remains limited by restricted procedural capacity, evolving clinical evidence, and uneven geographic adoption.

As additional devices receive regulatory approvals and CE marking, manufacturers will be able to expand into a multibillion-dollar adjacent addressable market by utilizing existing structural heart sales teams, imaging capabilities, and physician training programs. These procedures generally command higher average selling prices and stronger service-line profitability than conventional coronary interventions.

Manufacturers with an established TAVR presence are well positioned to leverage existing referral networks, cardiac imaging infrastructure, and physician relationships to accelerate adoption of tricuspid, pulmonary, and congenital heart therapies, creating stronger long-term growth opportunities through 2035.

Regional Analysis

North America Emerges as the Leading Regional Market for Interventional Cardiology Devices in 2025.

North America dominated the Interventional Cardiology Devices Market in 2025, accounting for over 41.0% of the global market share with revenue of approximately US$ 7.2 billion. The region’s leadership is supported by the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, strong adoption of minimally invasive cardiac procedures, and the presence of leading medical device manufacturers.

According to the Centers for Disease Control and Prevention, cardiovascular disease remains one of the leading causes of mortality in the United States, driving demand for coronary interventions, angioplasty procedures, and advanced stent technologies. The region benefits from widespread availability of catheterization laboratories, skilled interventional cardiologists, and favorable reimbursement frameworks that encourage adoption of innovative devices.

The United States contributes the majority of North America’s market revenue due to high procedure volumes for percutaneous coronary interventions (PCI), increasing utilization of drug-eluting stents, and growing investments in next-generation cardiovascular technologies.

Canada also supports regional growth through improvements in cardiac care infrastructure and increasing access to minimally invasive treatment options. Europe represents another significant market, driven by rising cardiovascular disease burden, established healthcare systems, and adoption of advanced coronary intervention technologies.

Meanwhile, Asia-Pacific is expected to witness strong growth due to increasing healthcare expenditure, expanding hospital infrastructure, and rising awareness of early cardiovascular diagnosis and treatment. Emerging economies are improving access to interventional cardiology procedures, creating long-term opportunities for market expansion.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

The Interventional Cardiology Devices Market is moderately consolidated, with leading multinational medical device companies holding significant market positions through broad product portfolios, strong distribution networks, and continuous technological advancements. Competitive dynamics are shaped by innovation in coronary stents, balloon catheters, guidewires, imaging systems, and minimally invasive cardiovascular intervention solutions.

Companies are increasingly focusing on R&D investments, strategic partnerships, product innovation, and integrated procedural ecosystems to improve clinical outcomes, enhance workflow efficiency, and expand global access to advanced cardiac care.

Medtronic plc, Abbott Laboratories, and Boston Scientific Corporation maintain strong competitive positions through next-generation stent platforms, catheter technologies, and comprehensive interventional cardiology solutions.

These companies emphasize clinical research, physician training programs, and partnerships with healthcare providers to strengthen adoption of advanced procedures. Terumo Corporation and B. Braun Melsungen AG focus on precision devices, vascular access solutions, and procedural safety improvements.

Other key participants, including Cardinal Health Inc., Philips Healthcare, Siemens Healthineers AG, GE HealthCare, Cook Medical, Cordis, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Meril Life Sciences, and Lepu Medical Technology compete through product diversification, regional expansion, digital workflow integration, and ecosystem-based cardiovascular care solutions.

Top Key Players

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• Cardinal Health Inc.
• Philips Healthcare
• Siemens Healthineers AG
• GE HealthCare
• Cook Medical
• Cordis (Cardinal Health)
• MicroPort Scientific Corporation
• Biotronik SE & Co. KG
• Meril Life Sciences
• Lepu Medical Technology

Recent Developments

• In January 2025, Boston Scientific Corporation announced an agreement to acquire Bolt Medical, strengthening its interventional cardiology portfolio with next-generation intravascular lithotripsy (IVL) technology. The acquisition strategy focused on expanding treatment options for complex calcified coronary and peripheral artery disease, where calcium modification remains a major challenge during minimally invasive procedures.
• In January 2025, Abbott Laboratories introduced Navitor™ Vision, an enhanced transcatheter aortic valve implantation (TAVI/TAVR) technology designed to improve valve positioning visibility during procedures. The product development reflects Abbott’s continued focus on precision-based structural heart interventions and improving procedural confidence for physicians.
• In February 2026, Medtronic plc announced its intent to acquire CathWorks, following a previous strategic partnership established in 2022. The acquisition, valued up to $585 million, strengthens Medtronic’s interventional cardiology portfolio by adding CathWorks’ FFRangio System for non-invasive coronary artery disease assessment.
• In June 2025, Terumo Corporation partnered with MedHub-AI to commercialize AutocathFFR™, an AI-based fractional flow reserve assessment solution in Japan. The agreement reflects growing industry movement toward integrating artificial intelligence into interventional cardiology workflows to simplify coronary physiology evaluation.

Report Scope